For more information, visit: http://usa.healthcare.siemens.com/clinical-specialities/oncology



1 NEOliquid is not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

2 National Lung Screening Trial. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med;2011:395-409

3 http://seer.cancer.gov/statfacts/html/prost.html

4 Grey A, et al. BJU International 2014; doi: 10.1111/bju.12862

5 Thian YL, et al. Academic Radiology 2014;21:531-7



Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world's largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of gas and steam turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2015, which ended on September 30, 2015, Siemens generated revenue of €75.6 billion and net income of €7.4 billion. At the end of September 2015, the company had around 348,000 employees worldwide. Further information is available on the Internet at www.siemens.com.

Back to HCB News

US Press Room Homepage